Thomas Oconnell, MD
Endocrinology, Diabetes & Metabolism · Burlington, NCNPI 1710047311
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $710,599 of the $804,781 with a category attached, or 88.3%. 22 manufacturers reported payments, led by Lilly USA, LLC at 44.1% of the total. Among endocrinology, diabetes & metabolism clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,532 payments — averaging $525.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$355K
- Novo Nordisk$231K
- Insulet Corporation$122K
- Sanofi-aventis U.S. LLC$80K
- Boehringer Ingelheim$10K
- AstraZeneca$5K
- plus $2K from 16 others
What the payments were for
- Consulting fees$12,6112%
- Speaking & faculty fees$710,59988%
- Travel & lodging$59,6177%
- Food & beverage$21,8703%
- Education$840%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 769 | $354,953 |
| Novo Nordisk | 319 | $230,630 |
| Insulet Corporation | 236 | $121,825 |
| Sanofi-aventis U.S. LLC | 87 | $79,765 |
| Boehringer Ingelheim | 40 | $10,386 |
| AstraZeneca | 5 | $4,872 |
| Abbott | 32 | $602 |
| Dexcom, Inc. | 9 | $391 |
| Madrigal Pharmaceuticals | 3 | $345 |
| Sequel Med Tech, LLC | 2 | $216 |
| Ascendis Pharma Endocrinology Inc | 6 | $184 |
| BETA Bionics, Inc. | 1 | $172 |
| Mannkind Corporation | 6 | $98 |
| Radius Health, Inc. | 4 | $80 |
| Shire North American Group Inc | 1 | $63 |
| Cequr Corporation | 3 | $44 |
| Ancora Heart, Inc. | 2 | $37 |
| Tandem Diabetes Care, Inc. | 2 | $32 |
| Xeris Pharmaceuticals, Inc. | 2 | $30 |
| Medtronic | 1 | $23 |
| Ascensia Diabetes Care US Inc. | 1 | $19 |
| Acella Pharmaceuticals, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$141,992
- TRULICITY$119,807
- Omnipod$118,035
- Ozempic$107,535
- TZIELD$67,166
- RYBELSUS$65,910
- JARDIANCE$35,285
- Tresiba$31,760
- HUMULIN$31,682
- FARXIGA$4,770
- Saxenda$2,040
- iLet Bionic Pancreas$516
- REZDIFFRA$345
- DEXCOM G6 TRANSMITTER$242
- TWIIST$202
- iLet Insulin Infusion Kit Inset$172
- iLet Insulin Infusion Kit Contact Detach$172
- TRICLIP$152
- Yorvipath$122
How this compares
$804,781 in reported general payments places this provider in the 95th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
See all endocrinology, diabetes & metabolism providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 778 | $831,809 |
| MounjaroTirzepatide | 391 | $479,997 |
| JardianceEmpagliflozin | 509 | $372,289 |
| TrulicityDulaglutide | 172 | $220,564 |
| Tresiba Flextouch U-200Insulin Degludec | 179 | $208,047 |
| ProliaDenosumab | 64 | $109,957 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 63 | $108,140 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 73 | $82,609 |
| FarxigaDapagliflozin Propanediol | 107 | $79,865 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 42 | $74,337 |
| JanuviaSitagliptin Phosphate | 75 | $69,029 |
| Tresiba Flextouch U-100Insulin Degludec | 118 | $68,912 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 64 | $59,975 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 51 | $59,769 |
| Humalog Kwikpen U-200Insulin Lispro | 25 | $42,467 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Fiasp, Novolog, Wegovy | $230,630 | $960,925938 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $354,953 | $719,260652 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $10,386 | $456,541593 claims |
| AstraZenecaFarxiga | $4,872 | $79,865107 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $79,765 | $65,16999 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.
Other endocrinology, diabetes & metabolism in Burlington
- Anna SolumBurlington$29K
- Mark WarrenGreenville$915K
- Corey BerlinRaleigh$742K
- Michael FavoritoWilmington$723K
- Stephen SouthGreensboro$624K
- Richard DoddAsheville$526K
- Wendy LaneAsheville$487K
- Victor MarlarAsheville$483K
- John BuseChapel Hill$460K
- Denis BeckerRaleigh$459K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.